EP1377287A4 - PROANTHOCYANIDINE FOR THE TREATMENT OF AMYLOID AND ALPHA SYNUCLEIN DISEASES - Google Patents

PROANTHOCYANIDINE FOR THE TREATMENT OF AMYLOID AND ALPHA SYNUCLEIN DISEASES

Info

Publication number
EP1377287A4
EP1377287A4 EP02719009A EP02719009A EP1377287A4 EP 1377287 A4 EP1377287 A4 EP 1377287A4 EP 02719009 A EP02719009 A EP 02719009A EP 02719009 A EP02719009 A EP 02719009A EP 1377287 A4 EP1377287 A4 EP 1377287A4
Authority
EP
European Patent Office
Prior art keywords
proanthocyanidines
amyloses
synuclein
alpha
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02719009A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1377287A2 (en
Inventor
Alan D Snow
Geraldo M Castillo
Paula Y Choi
Beth P Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoTech Inc
Original Assignee
ProteoTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/938,987 external-priority patent/US6607758B2/en
Priority claimed from PCT/US2001/051131 external-priority patent/WO2002042429A2/en
Application filed by ProteoTech Inc filed Critical ProteoTech Inc
Publication of EP1377287A2 publication Critical patent/EP1377287A2/en
Publication of EP1377287A4 publication Critical patent/EP1377287A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EP02719009A 2001-03-15 2002-02-15 PROANTHOCYANIDINE FOR THE TREATMENT OF AMYLOID AND ALPHA SYNUCLEIN DISEASES Withdrawn EP1377287A4 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US938987 1997-09-26
US27686601P 2001-03-15 2001-03-15
US276866P 2001-03-15
US09/938,987 US6607758B2 (en) 1997-05-15 2001-08-24 Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
PCT/US2001/051131 WO2002042429A2 (en) 2000-11-03 2001-11-02 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
US53625 2001-11-02
US10/053,625 US6929808B2 (en) 2000-11-03 2001-11-02 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
WOPCT/US05/01131 2001-11-02
US33872101P 2001-12-04 2001-12-04
US338721P 2001-12-04
US33903301P 2001-12-10 2001-12-10
US33896901P 2001-12-10 2001-12-10
US338969P 2001-12-10
US339033P 2001-12-10
PCT/US2002/004764 WO2002076381A2 (en) 2001-03-15 2002-02-15 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases

Publications (2)

Publication Number Publication Date
EP1377287A2 EP1377287A2 (en) 2004-01-07
EP1377287A4 true EP1377287A4 (en) 2007-11-14

Family

ID=56290250

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02719009A Withdrawn EP1377287A4 (en) 2001-03-15 2002-02-15 PROANTHOCYANIDINE FOR THE TREATMENT OF AMYLOID AND ALPHA SYNUCLEIN DISEASES

Country Status (6)

Country Link
EP (1) EP1377287A4 (enExample)
JP (1) JP4380991B2 (enExample)
AU (1) AU2002250117B2 (enExample)
CA (1) CA2441099C (enExample)
NZ (1) NZ528322A (enExample)
WO (1) WO2002076381A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
PT1511710E (pt) * 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
CA2499549C (en) * 2002-10-11 2012-01-24 Proteotech, Inc. Isolation, purification and synthesis of procyanidin b2 and uses thereof
JP2006232670A (ja) * 2003-05-20 2006-09-07 Ajinomoto Co Inc 神経障害用薬剤
WO2005082351A1 (ja) * 2004-03-02 2005-09-09 Eisai R & D Management Co., Ltd. 神経変性疾患治療剤
DK2004155T3 (en) * 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
WO2009104556A1 (ja) * 2008-02-19 2009-08-27 株式会社岐阜セラツク製造所 組成物
JP5738755B2 (ja) * 2008-05-09 2015-06-24 アイカーン スクール オブ メディシン アット マウント シナイ 神経変性疾患を予防および治療するための方法
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
CN107530385A (zh) 2015-05-11 2018-01-02 株式会社明治 用于促进脑源性神经营养因子产生的组合物
KR102441381B1 (ko) * 2016-07-18 2022-09-07 (주)아모레퍼시픽 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물
WO2021193703A1 (ja) * 2020-03-24 2021-09-30 学校法人 芝浦工業大学 中枢神経賦活組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
WO1999045797A1 (en) * 1998-03-12 1999-09-16 Mars, Incorporated Products containing polyphenol(s) and l-arginine to stimulate nitric oxide production
WO2000030666A1 (en) * 1998-11-24 2000-06-02 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
WO2001049307A1 (en) * 1999-12-30 2001-07-12 Proteotech, Inc. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
AU3886200A (en) * 1999-03-15 2000-10-16 Proteotech, Inc. Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
WO1999045797A1 (en) * 1998-03-12 1999-09-16 Mars, Incorporated Products containing polyphenol(s) and l-arginine to stimulate nitric oxide production
WO2000030666A1 (en) * 1998-11-24 2000-06-02 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
WO2001049307A1 (en) * 1999-12-30 2001-07-12 Proteotech, Inc. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses

Also Published As

Publication number Publication date
CA2441099A1 (en) 2002-10-03
CA2441099C (en) 2011-04-19
JP4380991B2 (ja) 2009-12-09
EP1377287A2 (en) 2004-01-07
WO2002076381A3 (en) 2002-11-21
WO2002076381A2 (en) 2002-10-03
AU2002250117B8 (en) 2002-10-08
AU2002250117B2 (en) 2007-11-29
JP2005505497A (ja) 2005-02-24
NZ528322A (en) 2005-03-24

Similar Documents

Publication Publication Date Title
FR14C0028I2 (fr) Derives de phenethanolamine destines au traitement de maladies respiratoires
DZ3500A1 (fr) Derives de phenethanolamine pour le traitement de maladies respiratoires
EP1572116A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
DE60226702D1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
EP1465854A4 (en) CHALCON DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISEASES
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60032823D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
PL374118A1 (en) Interleukin-1 receptors in the treatment of diseases
FIU20060389U0 (fi) Luusairauksien hoito
EP1529054A4 (en) THERAPEUTIC PROTEIN AND TREATMENTS
PT1392292E (pt) Piranoindazoles e sua utilizacao para o tratamento de glaucoma
EP1311261A4 (en) MEDICAMENTS FOR THE CHEMOTHERAPEUTIC TREATMENT OF ILLNESSES
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
MA28806B1 (fr) Derives d'arylsulfonylstilbene destines au traitement de l'insomnie et de conditions apparentees
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
EP1416964A4 (en) TREATMENT AND PREVENTION OF CANNULAR AND PRECULTURAL STATES OF LIVER, LUNGE AND ÖSOPHAGUS
EP1536829A4 (en) METHOD FOR PRODUCING COMPOSITIONS WITH HEAT SHOCK PROTEINS OR ALPHA-2-MACROGLOBULIN FOR THE TREATMENT OF CANCER AND INFECTION DISEASES
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
EP1460900A4 (en) Human secreted proteins
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
EP1416957A4 (en) TREATMENT OF DISORDERS RELATING TO IMMUNE CELLS AND B CELLS
NO20033123L (no) Terapeutisk hinne dannende sammensetning og behandlingsplan derav
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030924

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NGUYEN, BETH, P.

Inventor name: CHOI, PAULA, Y.

Inventor name: CASTILLO, GERALDO, M.

Inventor name: SNOW, ALAN, D.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20070717BHEP

Ipc: A61P 25/28 20060101ALI20070717BHEP

Ipc: A61P 25/16 20060101ALI20070717BHEP

Ipc: A61K 31/353 20060101ALI20070717BHEP

Ipc: A61K 31/352 20060101ALI20070717BHEP

Ipc: A61K 31/35 20060101AFI20070717BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071016

17Q First examination report despatched

Effective date: 20090618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120925